Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Spermicide

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,876 result(s) found for: Spermicide. Displaying page 1 of 94.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2018-003167-54 Sponsor Protocol Number: EIG-LNF-011 Start Date*: 2019-06-24
    Sponsor Name:Eiger BioPharmaceuticals, Inc.
    Full Title: A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID with and without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared...
    Medical condition: The proposed indication for lonafarnib coadministered with ritonavir is for the treatment of chronic HDV infection. Approximately 5% of HBV-infected individuals are infected with HDV worldwide. Ch...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10019763 Hepatitis delta LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) FR (Completed) BG (Completed) GR (Completed) ES (Ongoing) SE (Completed) IT (Completed) RO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004188-38 Sponsor Protocol Number: PHX401-14 Start Date*: 2017-12-14
    Sponsor Name:LABORATOIRE INNOTECH INTERNATIONAL
    Full Title: Contraceptive Efficacy, Tolerance and Acceptability of A Benzalkonium Chloride Spermicide Cream In Women Aged Over 40 Years of Age - PHASE IV, INTERNATIONAL, OPEN-LABEL, MULTICENTRE, PROSPECTIVE STUDY
    Medical condition: The current study is conducted in adult women over 40 years of age who need a contraceptive method and who accept to use a spermicide, according to the following inclusion/exclusion criteria and af...
    Disease: Version SOC Term Classification Code Term Level
    19.1 10042613 - Surgical and medical procedures 10067045 Chemical contraception PT
    Population Age: Adults Gender: Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002780-42 Sponsor Protocol Number: TR701-111 Start Date*: 2015-06-29
    Sponsor Name:Trius Therapeutics [...]
    1. Trius Therapeutics
    2. Cubist Pharmaceuticals, Inc
    Full Title: A Phase 1, Open-Label, Multi-Center, Two-Part, Single-Dose, Parallel Design, Safety, Tolerance, and Pharmacokinetic Study of Orally and Intravenously Administered TR-701 FA in 12 to 17 Year Old Ad...
    Medical condition: Acute bacterial skin and skin structure infections
    Disease: Version SOC Term Classification Code Term Level
    18.0 10022891 - Investigations 10040879 Skin investigations HLGT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-003005-41 Sponsor Protocol Number: CS0866-A-U101 Start Date*: 2015-07-24
    Sponsor Name:Sankyo Pharma Development
    Full Title: A Comparative, Randomized, Single-Dose, 2-Way Crossover Bioavailability Study of a Compounded 4 mg/mL Olmesartan Medoxomil Suspension (Total Dose 40 mg) and 40 mg Olmesartan Medoxomil Tablets (Beni...
    Medical condition: Not applicable - Healthy Volunteer study
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-005345-36 Sponsor Protocol Number: D5610C00001 Start Date*: 2014-05-13
    Sponsor Name:Ardelyx, Inc.
    Full Title: An exploratory Phase 2, randomized, double-blind, placebo-controlled, parallel design study to evaluate the safety, tolerability, and pharmacodynamics of AZD1722 in CKD patients with type 2 diabete...
    Medical condition: Chronic kidney disease (CKD) with type 2 diabetes mellitus and albuminuria
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004857 10064848 Chronic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020832-20 Sponsor Protocol Number: P06356 Start Date*: 2010-08-13
    Sponsor Name:Schering-Plough Research Institute, a Division of Schering Corporation - for Global trials
    Full Title: An Evaluation of the Safety and Pharmacokinetics of Posaconazole (POS, SCH 56592) IV Solution via Peripheral Administration in Healthy Volunteers (P06356)
    Medical condition: This study is going to be conducted in heathy volunteers.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2005-004859-35 Sponsor Protocol Number: 250518BS Start Date*: 2006-06-07
    Sponsor Name:G&W Laboratories, Inc.
    Full Title: Determination of antipsoriatic efficacy of topical formulations and comparison to a brand medication and placebo in a psoriasis plaque test
    Medical condition: Male or female subjects aged 18 to 64 are eligible for the study insofar that they suffer from chronic plaque type psoriasis.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-000757-21 Sponsor Protocol Number: P04823 Start Date*: 2006-08-15
    Sponsor Name:AESCA Pharma GmbH
    Full Title: Study to evaluate Response Rates in CHC Patients genotype 1 with Insulin Resistance and to assess prolonged Treatment Duration in late virological Responders
    Medical condition: chronic hepatitis C, genotype 1
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-002317-40 Sponsor Protocol Number: 280210BS Start Date*: 2008-10-17
    Sponsor Name:Perrigo Israel Pharmaceuticals Ltd.
    Full Title: A phase IIa, multi-center, randomized, double-blind, vehicle-controlled study to determine antipsoriatic efficacy and safety of topical CEP-701 (lestaurtinib) cream formulations in patients with ps...
    Medical condition: Chronic plaque type psoriasis of mild to moderate severity, at least one plaque with a treatment area of approximately 25 - 50 cm2
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001188-58 Sponsor Protocol Number: IDIT001 Start Date*: 2022-02-16
    Sponsor Name:Göteborgs Universitet
    Full Title: The effect of anti-IL17 in new-onset type 1 diabetes: a randomized, double-blind, placebo-controlled trial
    Medical condition: Type 1 diabetes
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-006951-32 Sponsor Protocol Number: REP0321 Start Date*: 2022-04-05
    Sponsor Name:Dompé farmaceutici s.p.a.
    Full Title: Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multina...
    Medical condition: COVID-19 and other community-acquired pneumonia
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10010120 Community acquired pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) IT (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003936-25 Sponsor Protocol Number: RLX0120 Start Date*: 2020-10-31
    Sponsor Name:DOMPé FARMACEUTICI S.P.A.
    Full Title: Multicenter, adaptive, randomized, placebo-controlled, double blind, parallel-group Phase 2/3 trial, to study efficacy and safety of two doses of raloxifene in adult paucisymptomatic COVID-19 patie...
    Medical condition: Adult paucisymptomatic COVID-19 patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10047438 Viral infectious disorders HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-004687-47 Sponsor Protocol Number: M10-255 Start Date*: 2008-04-02
    Sponsor Name:Abbott GmbH & Co. K.G.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind Study Comparing the Safety and Efficacy of ABT-874 to Methotrexate in Subjects with Moderate to Severe Chronic Plaque Psoriasis.
    Medical condition: Moderate to severe chronic plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037153 Psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SE (Completed) GB (Completed) ES (Completed) FR (Completed) AT (Completed) BE (Completed) DK (Completed) GR (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-005955-40 Sponsor Protocol Number: M10-016 Start Date*: 2009-03-25
    Sponsor Name:Abbott GmbH & Co. K.G.
    Full Title: A Phase 3, Multi-center, Open-label Continuation Study in Moderate to Severe Chronic Plaque Psoriasis Subjects who Completed a Preceding Psoriasis Study With ABT-874
    Medical condition: Moderate to severe chronic plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037153 Psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) FI (Prematurely Ended) FR (Completed) BE (Completed) AT (Prematurely Ended) ES (Prematurely Ended) SE (Completed) DK (Prematurely Ended) IT (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-002095-24 Sponsor Protocol Number: H9X-MC-GBGE(b) Start Date*: 2015-11-16
    Sponsor Name:Eli LIlly and Company
    Full Title: Protocol H9X-MC-GBGE(b) A Randomized, Parallel-Arm, Double-Blind Study of Efficacy and Safety of Dulaglutide When Added to SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus (AWARD-10: As...
    Medical condition: Type 2 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    19.0 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) CZ (Completed) AT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-019991-55 Sponsor Protocol Number: CC-10004-PSOR-008 Start Date*: 2011-01-25
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 3, multicenter, randomized, double-blind, placebo-controlled, efficacy and safety study of Apremilast (CC-10004) in subjects with moderate to severe plaque psoriasis
    Medical condition: Psoriasis, a chronic inflammatory skin disorder, estimated to affect up to 2.5% of the world's population. Plaque-type psoriasis is the most common form of this disease.
    Disease: Version SOC Term Classification Code Term Level
    18.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-003796-58 Sponsor Protocol Number: NAC-GED-0507-ACN-02-17 Start Date*: 2017-12-13
    Sponsor Name:PPM SERVICES S.A.
    Full Title: AN OPEN LABEL CLINICAL STUDY TO EVALUATE THE LONG-TERM DERMAL SAFETY PROFILE OF 12-WEEKS TOPICAL ADMINISTRATION OF N-ACETYL-GED-0507-34-LEVO GEL 5% IN PATIENTS WITH FACIAL ACNE
    Medical condition: FACIAL ACNE
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10000519 Acne vulgaris LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-018386-32 Sponsor Protocol Number: CC-10004-PSA-003 Start Date*: 2010-12-27
    Sponsor Name:Celgene Corporation
    Full Title: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF TWO DOSES OF APREMILAST (CC-10004) IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS
    Medical condition: Psoriatic arthritis, an inflammatory arthritis that occurs in 6-39% of psoriasis patients
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) EE (Completed) GB (Completed) BE (Completed) DE (Completed) HU (Completed) ES (Completed) IT (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2013-002518-11 Sponsor Protocol Number: 8835-004 Start Date*: 2014-01-16
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS CARDIOVASCULAR OUTCOMES FOLLOWING TREATMENT WITH ERTUGLIFLOZIN (MK-8835/PF-04971729) IN SUBJECTS WITH TYPE 2 DIABETES ME...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) NL (Completed) GB (Completed) IT (Completed) ES (Completed) BG (Completed) PL (Completed) GR (Completed) HR (Completed) SK (Completed) LT (Completed) LV (Completed) CZ (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2004-000091-14 Sponsor Protocol Number: FFR102123 Start Date*: 2004-09-17
    Sponsor Name:GlaxoSmithKline, S.A
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre, Long-Term Study to Evaluate the Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg ...
    Medical condition: Perennial allergic rhinitis
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) SE (Completed) LV (Completed) LT (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 07 21:48:08 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA